Form 8-K - Current report:
SEC Accession No. 0000875045-25-000035
Filing Date
2025-07-31
Accepted
2025-07-31 06:13:54
Documents
14
Period of Report
2025-07-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K biib-20250731.htm   iXBRL 8-K 24082
2 EX-99.1 exhibit991-q22025pressrele.htm EX-99.1 555547
6 newbiogenlogo.jpg GRAPHIC 2811
  Complete submission text file 0000875045-25-000035.txt   739084

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT biib-20250731.xsd EX-101.SCH 1804
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT biib-20250731_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT biib-20250731_pre.xml EX-101.PRE 12526
16 EXTRACTED XBRL INSTANCE DOCUMENT biib-20250731_htm.xml XML 2692
Mailing Address 225 BINNEY STREET CAMBRIDGE MA 02142
Business Address 225 BINNEY STREET CAMBRIDGE MA 02142 7814642000
BIOGEN INC. (Filer) CIK: 0000875045 (see all company filings)

EIN.: 330112644 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-19311 | Film No.: 251169183
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)